Related references
Note: Only part of the references are listed.Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer
Christopher M. Bailey et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
The Hippo Pathway: Biology and Pathophysiology
Shenghong Ma et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Stabilization of HIF-1α and HIF-2α, up-regulation of MYCC and accumulation of stabilized p53 constitute hallmarks of CNS-PNET animal model
Sergey Malchenko et al.
PLOS ONE (2017)
Waste disposal-An attractive strategy for cancer therapy
Jemilat Salami et al.
SCIENCE (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies
E. Lasorsa et al.
CELL DEATH & DISEASE (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery
Boya Liu et al.
MEDICAL ONCOLOGY (2014)
Small RNA combination therapy for lung cancer
Wen Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
MYC Degradation
Amy S. Farrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Meital Gabay et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2013)
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Gregg L. Semenza
JOURNAL OF CLINICAL INVESTIGATION (2013)
Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1α-Dependent Phenotype Switching
Daniel S. Widmer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
HIF1A Overexpression Is Associated with Poor Prognosis in a Cohort of 731 Colorectal Cancers
Yoshifumi Baba et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways
Klaus Podar et al.
CELL CYCLE (2010)
Stabilization of Hypoxia-inducible Factor-1α Protein in Hypoxia Occurs Independently of Mitochondrial Reactive Oxygen Species Production
Yee Liu Chua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Ubiquitylation of the amino terminus of Myc by SCFβ-TrCP antagonizes SCFFbw7-mediated turnover
Nikita Popov et al.
NATURE CELL BIOLOGY (2010)
Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α-Dependent Pathway in Multiple Myeloma
Jing Zhang et al.
CANCER RESEARCH (2009)
Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia
Jun Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
p53 represses c-Myc through induction of the tumor suppressor miR-145
Mohit Sachdeva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells
Seung-Nam Jung et al.
CARCINOGENESIS (2008)
High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF
Andreas-Claudius Hoffmann et al.
NEOPLASIA (2008)
Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions
Benoit Vlaminck et al.
FEBS JOURNAL (2007)
Hypoxia-inducible factor I and dysregulated c-myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1
Jung-Whan Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The positive regulation of p53 by the tumor suppressor VHL
Jae-Seok Roe et al.
CELL CYCLE (2006)
The Myc oncoprotein as a therapeutic target for human cancer
Marina Vita et al.
SEMINARS IN CANCER BIOLOGY (2006)
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
DH Kong et al.
CANCER RESEARCH (2005)
Opinion - Analysis of genomic targets reveals complex functions of MYC
JH Patel et al.
NATURE REVIEWS CANCER (2004)
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells
ZR Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Genomic targets of the human c-Myc protein
PC Fernandez et al.
GENES & DEVELOPMENT (2003)
Chromatin association of human origin recognition complex, Cdc6, and minichromosome maintenance proteins during the cell cycle:: Assembly of prereplication complexes in late mitosis
J Méndez et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
